Eudaimonia Partners’s Fulgent Genetics FLGT Stock Holding History

Eudaimonia Partners’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-110	Closed	-$11K	–	696
2021 Q1	$11K	Buy	+110	New	+$11.4K	﹤0.01%	1134

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Eudaimonia Partners's FLGT Position: Q2 2021 in Review

Eudaimonia Partners sold out of Fulgent Genetics (FLGT) in Q2 2021, closing a stake of 110 shares — an estimated $11K sold.

Eudaimonia Partners first reported a position in FLGT in Q1 2021 and held it in 1 quarter. The position peaked at $11K in Q1 2021. 254 funds tracked by Wall St. Rank hold FLGT as of Q2 2021.

Eudaimonia Partners reported no remaining Fulgent Genetics position as of Q2 2021 after selling out during the quarter.
Eudaimonia Partners sold 110 Fulgent Genetics shares in Q2 2021, an estimated $11K.
Eudaimonia Partners first reported a position in Fulgent Genetics in Q1 2021 and held it in 1 quarter.
Eudaimonia Partners's Fulgent Genetics position peaked at $11K in Q1 2021.
254 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.